Quốc gia: Canada
Ngôn ngữ: Tiếng Anh
Nguồn: Health Canada
SERTRALINE (SERTRALINE HYDROCHLORIDE)
ACTAVIS PHARMA COMPANY
N06AB06
SERTRALINE
100MG
CAPSULE
SERTRALINE (SERTRALINE HYDROCHLORIDE) 100MG
ORAL
100/250
Prescription
SELECTIVE-SEROTONIN REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0123417002; AHFS:
CANCELLED POST MARKET
2018-07-09
Page 1 of 53 PRODUCT MONOGRAPH P PR ACT SERTRALINE Sertraline as Sertraline Hydrochloride Capsules, 25 mg, 50 mg and 100 mg ANTIDEPRESSANT / ANTIPANIC / ANTIOBSESSIONAL AGENT Actavis Pharma Company 6733 Mississauga Road, Suite 400 Mississauga, Ontario L5N 6J5 Control No.: 198893 Date of Revision: October 24, 2016 Page 2 of 53 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION .....................................................................3 INDICATIONS AND CLINICAL USE ...........................................................................3 CONTRAINDICATIONS ...............................................................................................4 WARNINGS AND PRECAUTIONS ..............................................................................5 ADVERSE REACTIONS .............................................................................................. 13 DRUG INTERACTIONS .............................................................................................. 21 DOSAGE AND ADMINISTRATION ........................................................................... 26 OVERDOSAGE ............................................................................................................ 28 ACTION AND CLINICAL PHARMACOLOGY .......................................................... 29 STORAGE AND STABILITY ...................................................................................... 32 SPECIAL HANDLING INSTRUCTIONS .................................................................... 32 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................... 32 PART II: SCIENTIFIC INFORMATION ............................................................................ 33 PHARMACEUTICAL INFORMATION....................................................................... 33 CLINICAL TRIALS................................................................................................ Đọc toàn bộ tài liệu